Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Symlin is a synthetic version of amylin, a neuroendocrine hormone secreted by pancreatic beta cells, that boosts insulin action and helps regulate appetite, food intake and glucose control.

Amylin is a hormone that helps regulate blood sugar levels and control appetite, while calcitonin is a metabolic hormone.

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

While semaglutide works by hampering appetite and controlling blood sugar levels by mimicking the GLP-1 hormone, cagrilintide ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

The first amylin drug was introduced to the market some 20 years ago ... The Danish drugmaker has already struggled to meet ...